2019EMN共识：接受卡非佐米治疗的骨髓瘤患者心脏不良事（反应）件的预防,检测和治疗.pdfVIP

DR. SARA BRINGHEN (Orcid ID : 0000-0003-4539-6363) Article type : Clinical guidelines EMN guideline article PREVENTION, MONITORING AND TREATMENT OF CARDIOVASCULAR ADVERSE EVENTS IN MYELOMA PATIENTS RECEIVING CARFILZOMIB A Consensus Paper by the European Myeloma Network and the Italian Society of Arteri- al Hypertension Sara Bringhen, MD,1* Alberto Milan, MD,2 Mattia DAgostino, MD, 1 Claudio Ferri, MD,3 Ralph Wäsch, MD,4 Francesca Gay, MD,1 Alessandra Larocca, MD,1 Massimo Offidani, MD,5 Sonja Zweegman, MD,6 Evangelos Terpos, MD,7 Hartmut Goldschmidt, MD,8 Michele Cavo, MD,9 Heinz Ludwig, MD,10 Christoph Driessen, MD,11 Holger Auner, MD PhD,12 Jo Caers, MD,13 Martin Gramatzki, MD,14 Meletios A Dimopoulos, MD,7 Mario Boccadoro, MD,1 Hermann Einsele, MD,15 Pieter Sonneveld, MD,16 Monika Engelhardt, MD4 1Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città del- la Salute e della Scienza di Torino, Torino, Italy; 2Dpt of Medical Sciences – Internal Medicine and Hypertension Division - University of Torino - AOU Città della Salute e della Scienza di Torino; Rete Oncologica Piemontese, Torino, Italy; 3University of LAquila, MeSVA Department - San Salvatore Hospital, Division of Internal Medicine Neph- rology, Coppito, Italy; 4Department of Medicine I, Hematology, Oncology Stem Cell Transplantation, Medical Center - Universi- ty of Freiburg, Faculty of Medicine, University of Freiburg, Germany; 5Clinica di Ematologia, AOU Ospedali Riuniti di Ancona, Ancona, Italy; 6Amsterdam UMC, Vrije Universiteit Amsterdam, VU University Medical Center, Department of Hematol o- gy, Cancer Center Amsterdam, Amsterdam 7Department of Clinical Therapeutics, National and Kapod